|
On the upside, shares of CEL-SCI Corp. /quotes/comstock/14*!cvm/quotes/nls/cvm (CVM 1.18, +0.16, +15.56%) shot up 20% to $1.23.
The vaccine developer said that it is beginning clinical testing of its experimental LEAPS immunology therapy for patients hospitalized with the H1N1 virus. Rating :
 (No ratings) |
54/Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|